Id |
Subject |
Object |
Predicate |
Lexical cue |
T38 |
0-10 |
Sentence |
denotes |
Patient 1: |
T39 |
11-222 |
Sentence |
denotes |
A 53-year old woman with a personal history of essential hypertension and Type 2 diabetes mellitus presented with symptoms of polypnea of more than 40 rpm, use of respiratory ancillary musculature and dry cough. |
T40 |
223-287 |
Sentence |
denotes |
She arrived from a foreign country where COVID-19 was spreading. |
T41 |
288-419 |
Sentence |
denotes |
Symptoms started on 23 March and COVID-19 was diagnosed on 26 March on the basis of positive real time PCR (RT-PCR) for SARS-CoV-2. |
T42 |
420-576 |
Sentence |
denotes |
Initial gasometry showed moderate hypoxemia and respiratory alkalosis with a partial pressure of oxygen/fraction of inspired oxygen (PO2/FiO2) ratio of 191. |
T43 |
577-638 |
Sentence |
denotes |
Chest x-rays showed interstitial lesions in both lung fields. |
T44 |
639-732 |
Sentence |
denotes |
She started therapy with lopinavir/ritonavir, chloroquine, recombinant IFN α-2b and rocephin. |
T45 |
733-886 |
Sentence |
denotes |
In spite of treatment, the illness subsequently progressed to hypoxemic respiratory failure warranting the initiation of invasive mechanical ventilation. |
T46 |
887-1071 |
Sentence |
denotes |
At day 13 of her admission in the ICU, she showed radiologic worsening of the interstitial multifocal pneumonia, with elevation of ALP, LDH, erythrocyte sedimentation rate and D-dimer. |
T47 |
1072-1127 |
Sentence |
denotes |
Physicians administered itolizumab at a dose of 200 mg. |
T48 |
1128-1256 |
Sentence |
denotes |
After 48 h of the first itolizumab dose, PO2/FiO2 improved and there were evidences of radiological improvement (Figure 1A & B). |
T49 |
1257-1363 |
Sentence |
denotes |
Patient was extubated after the first dose of the antibody and her status changed from critical to severe. |
T50 |
1364-1447 |
Sentence |
denotes |
She received a second dose of the antibody (200 mg), 48 h after the first infusion. |
T51 |
1448-1554 |
Sentence |
denotes |
3 days after the first administration, patient was hemodynamically stable and has spontaneous ventilation. |
T52 |
1555-1666 |
Sentence |
denotes |
IL-6 levels were evaluated before itolizumab administration and after 2 and 7 days of the first administration. |
T53 |
1667-1756 |
Sentence |
denotes |
IL-6 levels reduced overtime from 172 pg/ml to 60 pg/ml (day 7) as depicted in Figure 2A. |
T54 |
1757-1828 |
Sentence |
denotes |
IL-1 was evaluated at the same time intervals, but it was undetectable. |
T55 |
1829-1998 |
Sentence |
denotes |
In addition, aspartate amino transferase (AST) concentrations were evaluated at different time points showing a reduction from 43 U/l to 24 U/l after 7 days (Figure 2B). |
T56 |
1999-2055 |
Sentence |
denotes |
No adverse events related with itolizumab were reported. |